LLY Logo

Eli Lilly & Co (LLY) Stock Forecast & Price Prediction

Live LLY Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NYSE | Healthcare | Drug Manufacturers - General

$868.88

-9.43 (-1.07%)

12 Month Price Forecast For LLY

$868.88
Current Price
$775.79B
Market Cap
28 Ratings
Buy 21
Hold 6
Sell 1
Wall St Analyst Ratings

Distance to LLY Price Forecasts

+37.0%
To High Target of $1,190.00
+15.1%
To Median Target of $1,000.00
-28.6%
To Low Target of $620.00

LLY Price Momentum

+3.2%
1 Week Change
+8.6%
1 Month Change
+17.9%
1 Year Change
+12.5%
Year-to-Date Change
-10.7%
From 52W High of $972.53
+22.1%
From 52W Low of $711.40

๐Ÿค” Considering Eli Lilly (LLY)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 10:21 AM UTC

LLY Analyst Ratings & Price Targets

Based on our analysis of 38 Wall Street analysts, LLY has a bullish consensus with a median price target of $1,000.00 (ranging from $620.00 to $1,190.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $868.88, the median forecast implies a 15.1% upside. This outlook is supported by 21 Buy, 6 Hold, and 1 Sell ratings.

The most optimistic forecast comes from Peter Verdult at Citigroup, projecting a 37.0% upside. Conversely, the most conservative target is provided by David Toung at Argus Research, suggesting a 28.6% downside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

LLY Analyst Consensus

21
Buy
6
Hold
1
Sell

LLY Price Target Range

Low
$620.00
Average
$1,000.00
High
$1,190.00
Current: $868.88

Latest LLY Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for LLY.

Date Firm Analyst Rating Change Price Target
Feb 3, 2025 Truist Securities Srikripa Devarakonda Buy Maintains $1,038.00
Jan 28, 2025 Wells Fargo Mohit Bansal Overweight Maintains $970.00
Jan 28, 2025 Citigroup Peter Verdult Buy Maintains $1,190.00
Dec 10, 2024 B of A Securities Tim Anderson Buy Reinstates $997.00
Nov 15, 2024 Wolfe Research Alexandria Hammond Outperform Initiates $1,000.00
Nov 4, 2024 Deutsche Bank James Shin Buy Maintains $1,015.00
Oct 31, 2024 Barclays Carter Gould Overweight Maintains $975.00
Oct 31, 2024 B of A Securities Geoff Meacham Buy Maintains $1,100.00
Oct 25, 2024 Citigroup Peter Verdult Buy Maintains $1,250.00
Oct 17, 2024 Bernstein Outperform Initiates $1,100.00
Oct 10, 2024 Truist Securities Srikripa Devarakonda Buy Maintains $1,033.00
Oct 3, 2024 Deutsche Bank James Shin Buy Reiterates $1,025.00
Sep 16, 2024 Cantor Fitzgerald Louise Chen Overweight Reiterates $885.00
Sep 13, 2024 Citigroup Peter Verdult Buy Reinstates $1,060.00
Sep 13, 2024 JP Morgan Chris Schott Overweight Maintains $1,100.00
Sep 9, 2024 Cantor Fitzgerald Louise Chen Overweight Reiterates $885.00
Aug 27, 2024 Morgan Stanley Terence Flynn Overweight Reiterates $1,106.00
Aug 19, 2024 Cantor Fitzgerald Louise Chen Overweight Reiterates $885.00
Aug 16, 2024 Guggenheim Seamus Fernandez Buy Maintains $1,030.00
Aug 14, 2024 Berenberg Kerry Holford Buy Maintains $1,050.00

Stocks Similar to Eli Lilly & Co

The following stocks are similar to Eli Lilly based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Eli Lilly & Co (LLY) Financial Data

Eli Lilly & Co has a market capitalization of $775.79B with a P/E ratio of 73.9x. The company generates $40.86B in trailing twelve-month revenue with a 20.5% profit margin.

Revenue growth is +20.4% quarter-over-quarter, while maintaining an operating margin of +39.8% and return on equity of +65.3%.

Valuation Metrics

Market Cap $775.79B
Enterprise Value $785.18B
P/E Ratio 73.9x
PEG Ratio 38.1x
Price/Sales 19.0x

Growth & Margins

Revenue Growth (YoY) +20.4%
Gross Margin +81.0%
Operating Margin +39.8%
Net Margin +20.5%
EPS Growth +20.4%

Financial Health

Cash/Price Ratio +0.5%
Current Ratio 1.3x
Debt/Equity 218.1x
ROE +65.3%
ROA +13.9%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Eli Lilly & Co logo

Eli Lilly & Co (LLY) Company Overview

About Eli Lilly & Co

What They Do

Develops and markets human pharmaceuticals globally.

Business Model

The company generates revenue by discovering, developing, and marketing a diverse range of pharmaceuticals across multiple therapeutic areas, including diabetes, oncology, autoimmune diseases, and mental health. Its product portfolio includes well-known medications for chronic conditions, which are sold worldwide, and the company also invests in research and development to innovate and expand its offerings.

Additional Information

Eli Lilly operates the Lilly Seaport Innovation Center in Boston, focusing on RNA and DNA-based therapies, and has established collaborations with several leading pharmaceutical companies and research institutions to enhance drug development capabilities. Founded in 1876 and headquartered in Indianapolis, Indiana, the company has a long-standing history in the pharmaceutical sector.

Company Information

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

43,000

CEO

Mr. David A. Ricks

Country

United States

IPO Year

1972

Eli Lilly & Co (LLY) Latest News & Analysis

LLY stock latest news image
Quick Summary

Zacks.com users are increasingly focused on Lilly (LLY), indicating potential interest and movement in the stock. Investors may want to monitor developments closely.

Why It Matters

Increased interest in Lilly (LLY) could signal potential price movement or volatility, influencing investment strategies and portfolio decisions.

Source: Zacks Investment Research
Market Sentiment: Positive
LLY stock latest news image
Quick Summary

OliX and Eli Lilly have entered a global licensing agreement for the development and commercialization of OLX75016, targeting cardiometabolic indications.

Why It Matters

The licensing agreement between OliX and Eli Lilly signals potential growth in cardiometabolic treatments, likely boosting investor confidence and interest in both companies' stock performance.

Source: Business Wire
Market Sentiment: Neutral
LLY stock latest news image
Quick Summary

Why It Matters

Source: Business Wire
Market Sentiment: Neutral
LLY stock latest news image
Quick Summary

Identifying stocks that could potentially double in value within three years is challenging, even during the current bull market.

Why It Matters

The mention of potential for significant stock gains highlights investment opportunities, indicating market optimism but also the challenges in identifying high-growth stocks.

Source: 24/7 Wall Street
Market Sentiment: Positive
LLY stock latest news image
Quick Summary

MarketBeat monitors top-rated Wall Street analysts and their stock recommendations, providing insights into best-performing stocks for investors.

Why It Matters

MarketBeat's tracking of top analysts highlights stocks with strong recommendations, aiding investors in identifying potential high-performing investments.

Source: MarketBeat
Market Sentiment: Neutral
LLY stock latest news image
Quick Summary

Growth stocks outside the AI sector, particularly in healthcare, are gaining attention and may present investment opportunities.

Why It Matters

Diversifying beyond AI into other sectors like healthcare can uncover undervalued growth stocks, potentially leading to better returns and reduced risk in investment portfolios.

Source: The Motley Fool
Market Sentiment: Positive

Frequently Asked Questions About LLY Stock

What is Eli Lilly & Co's (LLY) stock forecast for 2025?

Based on our analysis of 38 Wall Street analysts, Eli Lilly & Co (LLY) has a median price target of $1,000.00. The highest price target is $1,190.00 and the lowest is $620.00.

Is LLY stock a good investment in 2025?

According to current analyst ratings, LLY has 21 Buy ratings, 6 Hold ratings, and 1 Sell ratings. The stock is currently trading at $868.88. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for LLY stock?

Wall Street analysts predict LLY stock could reach $1,000.00 in the next 12 months. This represents a 15.1% increase from the current price of $868.88. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Eli Lilly & Co's business model?

The company generates revenue by discovering, developing, and marketing a diverse range of pharmaceuticals across multiple therapeutic areas, including diabetes, oncology, autoimmune diseases, and mental health. Its product portfolio includes well-known medications for chronic conditions, which are sold worldwide, and the company also invests in research and development to innovate and expand its offerings.

What is the highest forecasted price for LLY Eli Lilly & Co?

The highest price target for LLY is $1,190.00 from Peter Verdult at Citigroup, which represents a 37.0% increase from the current price of $868.88.

What is the lowest forecasted price for LLY Eli Lilly & Co?

The lowest price target for LLY is $620.00 from David Toung at Argus Research, which represents a -28.6% decrease from the current price of $868.88.

What is the overall LLY consensus from analysts for Eli Lilly & Co?

The overall analyst consensus for LLY is bullish. Out of 38 Wall Street analysts, 21 rate it as Buy, 6 as Hold, and 1 as Sell, with a median price target of $1,000.00.

How accurate are LLY stock price projections?

Stock price projections, including those for Eli Lilly & Co, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.